



(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 35/00* (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:
PCT/US2018/051298

(22) International Filing Date:
17 September 2018 (17.09.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/559,330 15 September 2017 (15.09.2017) US
62/566,912 02 October 2017 (02.10.2017) US

(71) Applicant: **KITE PHARMA, INC.** [US/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US).

(72) Inventors: **SUSARCHICK, Debra**; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **UHRIN, John**; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **KORFIN, Michele**; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US).

(74) Agent: **NIEDERMEIER, Patrick** et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING




FIG. 1A

(57) Abstract: Methods and apparatuses are described for performing a patient-specific immunotherapy procedure. A computing device receives a request to create transduced T cells for a patient. The computing device generates a patient-specific identifier associated with the cell order request. The computing device initiates a process to create transduced T cells for infusion into the patient's bloodstream, comprising: performing a leukapheresis procedure on a sample of the patient's blood to collect T cells from the sample, transferring the collected T cells to a container, labeling the container with the patient-specific identifier, transmitting the collected T cells to a manufacturing facility, creating transduced T cells from the collected T cells using a cell modification technique, receiving the transduced T cells from the manufacturing facility, and infusing the transduced T cells into the patient's bloodstream. The computing

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

device records a tracking event for each step, including the patient-specific identifier, to generate a chain of custody of the patient's T cells.